Crossmark

Is there a link between very early changes of primary and secondary lymphoid organs in <sup>18</sup>F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?

Crossref DOI link: https://doi.org/10.1136/jitc-2020-000656

Published Online: 2020-08-04

Published Print: 2020-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Seith, Ferdinand https://orcid.org/0000-0002-9696-2954
Forschner, Andrea https://orcid.org/0000-0002-6185-4945
Weide, Benjamin

Gückel, Brigitte

Schwartz, Martin

Schwenck, Johannes

Othman, Ahmed E

Fenchel, Matthias

Garbe, Claus

Nikolaou, Konstantin

Schwenzer, Nina

la Fougère, Christian

Pfannenberg, Christina
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03132090 at ClinicalTrials.gov

Documents that mention this clinical trial

Is there a link between very early changes of primary and secondary lymphoid organs in <sup>18</sup>F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?
https://doi.org/10.1136/jitc-2020-000656
Funding

Funding for this research was provided by:

Wilhelm Sander-Stiftung (2014.157.1)
License Information

License valid from 2020-08-03

Document is current

Any future updates will be listed below